X4 Pharmaceuticals Inc. (XFOR) Becoming More Attractive for Investors

X4 Pharmaceuticals Inc.’s recently made public that its Director WYZGA MICHAEL S acquired Company’s shares for reported $29875.0 on Aug 18. In the deal valued at $1.20 per share,25,000 shares were bought. As a result of this transaction, WYZGA MICHAEL S now holds 76,667 shares worth roughly $ 99667.1.

Then, Stewart Murray sold 130,056 shares, generating $137,859 in total proceeds. Upon selling the shares at $1.06, the Interim Chief Medical Officer now owns 146,504 shares.

Before that, Mostafa Adam S. sold 2,641 shares. X4 Pharmaceuticals Inc. shares valued at $4,991 were divested by the Chief Financial Officer at a price of $1.89 per share. As a result of the transaction, Mostafa Adam S. now holds 80,221 shares, worth roughly $0.1 million.

PT values the company’s stock at a premium of 56.67 to its Tuesday closing price.

Price Performance Review of XFOR

On Tuesday, X4 Pharmaceuticals Inc. [NASDAQ:XFOR] saw its stock remained unchanged to $1.30. On the same session, the stock had its day’s lowest price of $1.25, but rose to a high of $1.33. Over the last five days, the stock has gained 0.78%. X4 Pharmaceuticals Inc. shares have risen nearly 30.92% since the year began. Nevertheless, the stocks have risen 25.00% over the past one year. While a 52-week high of $2.58 was reached on 06/13/23, a 52-week low of $0.65 was recorded on 03/28/23. SMA at 50 days reached $1.6112, while 200 days put it at $1.3781. A total of 2.02 million shares were traded, compared to the trading of 0.8 million shares in the previous session.

Levels Of Support And Resistance For XFOR Stock

The 24-hour chart illustrates a support level at 1.2567, which if violated will result in even more drops to 1.2133. On the upside, there is a resistance level at 1.3367. A further resistance level may holdings at 1.3733. The Relative Strength Index (RSI) on the 14-day chart is 42.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0362, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 32.00%. Stochastics %K at 68.00% indicates the stock is a holding.

How much short interest is there in X4 Pharmaceuticals Inc.?

A steep rise in short interest was recorded in X4 Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by -2.53 million shares to a total of 11.04 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 13.57 million shares. There was a decline of -22.92%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 6.73% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.36.

X4 Pharmaceuticals Inc. [XFOR] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 7,943,565 shares, or roughly 5.01% of the outstanding XFOR shares. In other words, the investor’s shares have risen by 7,627,005 from its previous 13-F filing of 316560.0. Additionally, The Vanguard Group, Inc. increased 76.18% of its stake after which the total value it holdings stand at $13,614,454. Over the last quarter, Millennium Management LLC purchased 4,371,397 shares of X4 Pharmaceuticals Inc., while Polar Capital LLP bought 5,000,000 shares. At present, Stonepine Capital Management LLC is holding 4,605,263 shares valued at $8.24 million. Adage Capital Management LP owned 4,276,315 shares of the company at the time of its most recent 13F filing, worth $7.65 million.

According to FactSet, X4 Pharmaceuticals Inc.’s share price will average $3.51 in the next year, based on opinions of analysts polled by the firm. This is up nearly 130.77 percent from its previous closing price of $1.30. Analysts expect X4 Pharmaceuticals Inc. stock to reach the higher price of $5.00, while the lowest price estimate is $2.60. However, 8 analysts have rated XFOR stock as a Buy in their predictions for 2023.